Search | IOVS | ARVO Journals

Showing 1 – 20 of 22

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2019

CEP290 -associated LCA due to a photoreceptor cilium defect treated with an intravitreal antisense oligonucleotide results in improved vision

Artur V Cideciyan; Samuel G Jacobson; Arlene V Drack; Allen C Ho; Alexandra Garafalo; Alejandro J Roman; Mike Schwartz; Patricia Biasutto; Wilma de Wit; Michael E Cheetham; Peter S Adamson; David Rodman; Julie De Zaeytijd; Caroline Van Cauwenbergh; Bart P Leroy; Stephen R Russell

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1834.

ARVO Annual Meeting Abstract July 2019

QR-421a, an antisense oligonucleotide, for the treatment of retinitis pigmentosa due to USH2A exon 13 mutations

Hester van Diepen; Kalyan Dulla; Hee Lam Chan; Iris Schulkens; Wouter Beumer; Lars Vorthoren; Cathaline den Besten; Levi Buil; Janne Turunen; Jiayi Miao; Sanne Broekman; Erik de Vrieze; Margo Dona; Silvia Albert; Erwin van Wijk; Peter S Adamson

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3250.

ARVO Annual Meeting Abstract July 2019

Allele specific knock-down of human P23H rhodopsin mRNA and prevention of retinal degeneration in humanized P23H rhodopsin knock-in mouse, following treatment with an intravitreal GAPmer antisense oligonucleotide (QR-1123)

Patricia Biasutto; Peter S Adamson; Kalyan Dulla; Sue Murray; Brett Monia; Michael McCaleb

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5719.

ARVO Annual Meeting Abstract July 2018

Relationship of severity of Fuchs endothelial corneal dystrophy with triplet repeat expansion in TCF4 and The Potential Implications to Surgical Intervention

Kirithika Muthusamy; Beatriz Sanchez-Pintado; Nathaniel Hafford Tear; Petra Liskova; Peter S Adamson; Alison J Hardcastle; Alice E Davidson; Stephen J. Tuft

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2920.

ARVO Annual Meeting Abstract July 2018

RNA toxicity induced by TCF4 CTG expansions is ameliorated by antisense therapeutics in a patient-derived cell model of Fuchs corneal endothelial dystrophy (FECD).

Alice E Davidson; Christina Zarouchlioti; Beatriz Sanchez-Pintado; Nathaniel Hafford Tear; Pontus Klein; Petra Liskova; Kalyan Dulla; Kirithika Muthusamy; Lubica Dudakova; Pavlina Skalicka; Pirro G Hysi; Michael E. Cheetham; Stephen J. Tuft; Peter S Adamson; Alison J Hardcastle

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3022.

ARVO Annual Meeting Abstract July 2018

Oligonucleotide-based splice correction of the ABCA4 c.5461-10T>C mutation in Stargardt disease type 1

Kalyan Dulla; Seda Yilmaz-Elis; Jiayi Miao; Iris Schmidt; Iris Schulkens; Hee Lam Chan; Peter S Adamson

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5315.

Biochemistry and Molecular Biology October 2015

Allele-Specific Inhibition of Rhodopsin With an Antisense Oligonucleotide Slows Photoreceptor Cell Degeneration

PDF

Susan F. Murray; Ali Jazayeri; Michael T. Matthes; Douglas Yasumura; Haidong Yang; Raechel Peralta; Andy Watt; Sue Freier; Gene Hung; Peter S. Adamson; Shuling Guo; Brett P. Monia; Matthew M. LaVail; Michael L. McCaleb
TAGS: alleles, antisense oligonucleotides, eye, mice, photoreceptors, rhodopsin, tissue degeneration, injections, painful bladder syndrome, rna
Invest. Ophthalmol. Vis. Sci.. 2015; 56(11):6362-6375. https://doi.org/10.1167/iovs.15-16400

ARVO Annual Meeting Abstract June 2015

Targeting P-TEFb recruitment and super-enhancers function suppress the development of Th1-mediated EAU disease

Malihe Eskandarpour; Arnulf Hertweck; Catherine Evans; Jonathan Lau; Audrey Kelley; Peter S Adamson; David Cousins; Virginia L Calder; Graham Lord; richard jenner

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2079.

ARVO Annual Meeting Abstract June 2015

Identification of a Human Clinical Candidate ASO Selectively Targeting the P23H Variant of Rhodopsin for the Treatment of P23H Rhodopsin-mediated ADRP

Sue F Murray; Ali Jazayeri; Raechel Peralta; Andy Watt; Timothy Vickers; Shuling Guo; Scott P Henry; Peter S Adamson; Brett p Monia; Michael McCaleb

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5402.

ARVO Annual Meeting Abstract June 2015

IL-18 immunotherapy for neovascular AMD; Tolerability and efficacy in non-human primates

Matthew Campbell; Peter S Adamson; Francisco J Lopez; Edit Kurali; Peter Humphries; Sarah Doyle

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4803.

ARVO Annual Meeting Abstract June 2015

Novel CCR3 antagonists are effective mono- and combination inhibitors of CNV growth and vascular permeability

Yin Shan Eric Ng; Norihiro Nagai; Meihua Ju; Kanako Izumi-Nagai; Scott Robbie; James W B Bainbridge; Achim H Krauss; David C Gale; Peter S Adamson; David Shima

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2290.

ARVO Annual Meeting Abstract June 2015

The role of LRG1 in the regulation of angiogenesis in Experimental Autoimmune Uveoretinitis.

Gemma Beers; Natasha Jeffs; David A Copland; Peter S Adamson; Virginia L Calder; Lindsay B Nicholson; Stephen E Moss; John Greenwood; Andrew D Dick

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2313.

ARVO Annual Meeting Abstract June 2015

A Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin , GSK2126458, Inhibits Laser-Induced Choroidal Neovascularization

Yu Sun; Jie Ma; Gianna C Teague; Francisco J Lopez; Peter S Adamson; Edit Kurali; Kameran Lashkari

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2364.

ARVO Annual Meeting Abstract June 2015

IL-18 promotes wound healing and has anti-angiogenic properties in the eye

Sarah Doyle; Peter S Adamson; Francisco J Lopez; Peter Humphries; Matthew Campbell

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2462.

ARVO Annual Meeting Abstract June 2015

Treatment of bacterial and viral conjunctivitis with topical ultrapure stable hypochlorous acid (HOCl): a clinical evaluation and treatment response in 79 cases

Peter S Adamson; Hendrik Roos; Jon von Holdt

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):280.

ARVO Annual Meeting Abstract April 2014

Functional role of TLR in choroidal neovascularization

Yin Shan Eric Ng; Meihua Ju; Daiju Iwata; Richard Foxton; Shannon Bunker; Monica Belich; Gerald Gough; Peter S Adamson; David T Shima

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1199.

ARVO Annual Meeting Abstract April 2014

NLRP3 independent mechanisms of RPE cell death

Matthew Campbell; Ema Ozaki; Marian M Humphries; Peter S Adamson; Peter Humphries; Sarah L Doyle

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1318.

ARVO Annual Meeting Abstract April 2014

Characterising the role of lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) in experimental autoimmune uveoretinitis (EAU)

Gemma Beers; Joanne Boldison; David Alexander Copland; Peter S Adamson; Lindsay B Nicholson; Andrew D Dick

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):2500.

ARVO Annual Meeting Abstract April 2014

Comparative analysis of retinal phenotype in Cfh -/- , Cfb -/- and Cfh -/- Cfb -/- double knock-out mice

Jennifer A E Williams; John Greenwood; Judy Latcham; Peter S Adamson; Stephen E Moss

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3450.

ARVO Annual Meeting Abstract March 2012

Lipoprotein-associated Phospholipase Inhibition Regulates Retinal Vasopermeability During Experimental Diabetes

Alan W. Stitt; Paul Canning; Philip J. Luthert; Josephiine V. Glenn; Lynsey-Dawn Allen; Vivien Prise; Peter S. Adamson

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5765.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

CEP290 -associated LCA due to a photoreceptor cilium defect treated with an intravitreal antisense oligonucleotide results in improved vision

QR-421a, an antisense oligonucleotide, for the treatment of retinitis pigmentosa due to USH2A exon 13 mutations

Allele specific knock-down of human P23H rhodopsin mRNA and prevention of retinal degeneration in humanized P23H rhodopsin knock-in mouse, following treatment with an intravitreal GAPmer antisense oligonucleotide (QR-1123)

Relationship of severity of Fuchs endothelial corneal dystrophy with triplet repeat expansion in TCF4 and The Potential Implications to Surgical Intervention

RNA toxicity induced by TCF4 CTG expansions is ameliorated by antisense therapeutics in a patient-derived cell model of Fuchs corneal endothelial dystrophy (FECD).

Oligonucleotide-based splice correction of the ABCA4 c.5461-10T>C mutation in Stargardt disease type 1

Allele-Specific Inhibition of Rhodopsin With an Antisense Oligonucleotide Slows Photoreceptor Cell Degeneration

Targeting P-TEFb recruitment and super-enhancers function suppress the development of Th1-mediated EAU disease

Identification of a Human Clinical Candidate ASO Selectively Targeting the P23H Variant of Rhodopsin for the Treatment of P23H Rhodopsin-mediated ADRP

IL-18 immunotherapy for neovascular AMD; Tolerability and efficacy in non-human primates

Novel CCR3 antagonists are effective mono- and combination inhibitors of CNV growth and vascular permeability

The role of LRG1 in the regulation of angiogenesis in Experimental Autoimmune Uveoretinitis.

A Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin , GSK2126458, Inhibits Laser-Induced Choroidal Neovascularization

IL-18 promotes wound healing and has anti-angiogenic properties in the eye

Treatment of bacterial and viral conjunctivitis with topical ultrapure stable hypochlorous acid (HOCl): a clinical evaluation and treatment response in 79 cases

Functional role of TLR in choroidal neovascularization

NLRP3 independent mechanisms of RPE cell death

Characterising the role of lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) in experimental autoimmune uveoretinitis (EAU)

Comparative analysis of retinal phenotype in Cfh -/- , Cfb -/- and Cfh -/- Cfb -/- double knock-out mice

Lipoprotein-associated Phospholipase Inhibition Regulates Retinal Vasopermeability During Experimental Diabetes

To View More...

You must be signed into an individual account to use this feature.